Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14864597 | 0.85 | NPSR1 (0.49) | NPSR1SRD5A2ALDH1A1MAPTHPGD | |
| SCHEMBL3053443 | 0.85 | NPSR1 (0.52) | NPSR1SRD5A2ALDH1A1MAPTHPGD | |
| SCHEMBL4155326 | 0.85 | PARP10 (0.50) | NPSR1SRD5A2ALDH1A1MAPTKLKB1 | |
| SCHEMBL8782245 | 0.84 | SMN1; SMN2 (0.56) | NPSR1ALDH1A1MAPTTDP1MEN1 | |
| SCHEMBL8783684 | 0.84 | NR4A2 (0.45) | ALDH1A1MAPTTDP1MEN1KMT2A | |
| SCHEMBL13687506 | 0.81 | NPSR1 (0.46) | NPSR1SRD5A2ALDH1A1MAPTMEN1 | |
| SCHEMBL10746960 | 0.80 | POLB (0.49) | SRD5A2ALDH1A1MAPTTDP1MEN1 | |
| SCHEMBL4673037 | 0.79 | ALDH1A1 (0.68) | NPSR1ALDH1A1MAPTTDP1MEN1 | |
| SCHEMBL6644449 | 0.78 | NR4A1 (0.44) | NPSR1ALDH1A1MAPTTDP1MEN1 | |
| SCHEMBL2868499 | 0.78 | PTGS1 (0.48) | NPSR1ALDH1A1MAPTTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-1951701-A2 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007017687-A2 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017687-A2 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| EP-0595995-B1 | ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1997-01-15 | — | — | EP | disclosed |
| US-5514702-A | Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0595995-A4 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0595995-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5214204-A | Inhibitors of biosynthesis of leukotrienes | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1993002037-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-02-04 | — | — | WO | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | PTGER3, PTGER2, CNR2 | NPSR1 66/4885SRD5A2 340/4885ALDH1A1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.